Prolonged complete remission of myelodysplastic syndrome treated with danazol, retinoic acid and low-dose prednisone

I Sadek, Irene Sadek, E. Zayed, O Hayne, Ormille A. Hayne, L. A. Fernández, L Fernandez
American journal of hematology · 2000 · vol. 64(4) , pp. 306–310 · doi:10.1002/1096-8652(200008)64:4<306::aid-ajh12>3.0.co;2-v · PMID:10911385 · W1979470678
Case report OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

A patient with myelodysplastic syndrome-refractory anemia achieved prolonged complete hematologic remission with danazol, retinoic acid, and low-dose prednisone combination therapy, lasting 86 months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Myelodysplastic syndrome (MDS) is a diverse group of clonal hematologic neoplasms. Different medications have been tried in MDS; however, no effective treatment has been yet established. We report a patient with MDS who achieved a complete remission in response to combination therapy of danazol, retinoic acid, and prednisone. A 53-year-old female presented with pancytopenia, macrocytosis, and hypercellular bone marrow with erythroid hyperplasia and dysplasia and 10% ringed sideroblasts. Cytogenetic studies revealed the presence of two abnormal clones. She was diagnosed as having MDS-refractory anemia and was given blood transfusions to maintain blood cell counts at acceptable levels. At the same time, she was started on a combination of danazol (600 mg/day), retinoic acid (100 mg/day), and prednisone (10 mg every other day). Fourteen months later, the patient was in complete hematologic remission; she had normal peripheral blood count, and the blood smear showed normal morphology. Bone marrow studies revealed normal trilineage hematopoiesis. She was continued on the same combination treatment for 86 months, and she remained in complete clinical remission. Eighty-eight months from diagnosis, she relapsed with acute myeloid leukemia. This is the first reported case of MDS-RA that sustained a complete hematologic remission for a prolonged period in response to this combination treatment. This report indicates that restoration of normal hematopoiesis, prolongation of disease-free survival, and delay in the transformation to acute leukemia may be achieved by this combination of treatment in a subset of patients with MDS, especially refractory anemia with severe thrombocytopenia.

My notes (saved in your browser only)

MeSH descriptors

Antineoplastic Agents Danazol Estrogen Antagonists Myelodysplastic Syndromes Prednisone Tretinoin Antineoplastic Agents Danazol Drug Therapy, Combination Estrogen Antagonists Female Humans Middle Aged Myelodysplastic Syndromes Myelodysplastic Syndromes Prednisone Remission Induction Tretinoin

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (29)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-11T05:55:38.273849+00:00
pubmed
last seen: 2026-10-08T20:59:30.381419+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0 · commercial use OK